Figure 6 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies

<p>Evaluation of dasatinib sensitivity in tB-TNBC models <i>in vitro</i> and <i>in vivo</i>. <b>A,</b> Dose–response curves showing cell viability of indicated cell lines treated with increasing concentrations of dasatinib for 72 hours. Solid lines represent the mean of three biological replicates performed in technical replicates normalized to untreated controls, and IC<sub>50</sub> values are indicated. <b>B,</b> Representative IHC images of tB-TNBC PDXs (PDX_01 and PDX_02) showing expression of SMA, TAGL, and TPM2. Scale bars, 100 μm. <b>C,</b> Quantification of positive tumor cells for each tB-marker in PDX_01 and PDX_02. Data are shown as mean ± SEM of different tumor areas. <b>D,</b> Schematic representation of the dasatinib treatment protocol. <b>E,</b> Tumor growth curves of the tB-TNBC PDXs treated with vehicle (black) or dasatinib (red). Error bars, ± SEM. <i>P</i> values calculated by Wilcoxon test. <b>F,</b> Bar plot showing tumor weight at the end point. Data are shown as mean ± SEM. <i>P</i> values calculated by two-tailed Student <i>t</i> test. **, <i>P</i> < 0.01. <b>D,</b> Created in BioRender. Rodilla, V. (2026) <a href="https://BioRender.com/qpb7bux" target="_blank">https://BioRender.com/qpb7bux</a>.</p>